This post was originally published on this site Tears in blood vessels of the heart can occur in people with cardiac sarcoidosis, a case report found, although the incidence of this complication appears to be low. The report, “Spontaneous coronary artery dissection in cardiac sarcoidosis,” was published in Oxford Medical Case Reports. Spontaneous coronary artery dissection…
This post was originally published on this site Treatment with the immunotherapy Keytruda (pembrolizumab) appears to be as effective as conventional chemotherapy for treating malignant pleural mesothelioma patients who relapse after one course of platinum-based chemotherapy, data from a Phase 3 trial show. Although more of these advanced cancer patients responded to Keytruda than to…
This post was originally published on this site The U.S. label of Nerlynx (neratinib), a treatment for early stage HER2-positive breast cancer, now includes information on the use of two anti-diarrheal medications to prevent severe side effects of the therapy. Puma Biotechnology, which markets Nerlynx, received approval from the U.S. Food and Drug Administration (FDA) to include…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved Zejula (niraparib) as a late-line treatment for women with advanced ovarian, fallopian tube, or primary peritoneal cancer who have tumors defective in DNA repair, a status termed “homologous recombination deficiency” (HRD), and have received at least three prior courses of…
This post was originally published on this site The European Medicines Agency (EMA) has recommended that Darzalex (daratumumab) be approved in Europe, in combination with Revlimid (lenalidomide) and dexamethasone, as a first-line treatment for multiple myeloma patients who are ineligible for autologous stem cell transplant (ASCT). Janssen announced the positive opinion by the EMA’s Committee for Medicinal Products for Human Use (CHMP) on…
This post was originally published on this site MEI Pharma’s experimental compound ME-401 reduced tumor burden in 78% of patients with relapsed or refractory follicular lymphoma and in 89% of those with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in an ongoing Phase 1b trial, the company announced. Responses were durable, updated…
This post was originally published on this site Blincyto (blinatumomab) increases overall survival and disease-free survival in children and adolescents with B-cell acute lymphoblastic leukemia (ALL) who already had their first relapse, data from Phase 3 trials show. Blincyto, developed by Amgen, is an antibody that binds to CD19, a protein found on the surface of…
This post was originally published on this site Bempegaldesleukin (bempeg, NKTR-214) in combination with Opdivo (nivolumab) leads to prolonged treatment responses in women with advanced or metastatic triple-negative breast cancer (TNBC), a Phase 1/2 trial shows. The findings were presented in a poster titled, “Clinical activity of BEMPEG plus NIVO observed in metastatic TNBC: preliminary…
This post was originally published on this site Men with prostate cancer who undergo surgery have similar long-term outcomes whether they receive radiation therapy shortly after the surgery or only when signs of disease recurrence appear, suggesting that some may be spared the radiation treatment, a Phase 3 clinical trial shows. Findings from the trial…
This post was originally published on this site A Phase 2 clinical trial is recruiting patients with untreated follicular lymphoma — the most common type of non-Hodgkin’s lymphoma — to study a combination of Aliqopa (copanlisib) and rituximab. The trial (NCT03789240) will be conducted at the National Institutes of Health Clinical Center, in Maryland, under the leadership…
